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Clinical PerspectiveWhat Is New?The association between radiotherapy for breast cancer and long‐term cardiovascular risk remains unclear.The meta‐analysis found that, in women diagnosed with breast cancer, risks of coronary heart disease and cardiac mortality were increased in patients with left‐sided radiotherapy compared with those with right‐sided radiotherapy, as well as in the comparison of patients with radiotherapy and those without radiotherapy.What Are the Clinical Implications?The meta‐analysis found that, in women diagnosed with breast cancer, radiotherapy increased the risks of coronary heart disease and cardiac mortality.Contemporary radiotherapy techniques have likely reduced the risk, but they may not have eliminated cardiotoxicity, and therefore the long‐term hazards in the general population still need to be monitored directly.The association between radiotherapy and cardiovascular risk has clinical relevance with respect to individual screening, risk factor modification, and the primary and secondary prevention of heart disease.

Introduction {#jah32266-sec-0008}
============

Breast cancer is the most common cancer in women, with over a million new cases diagnosed each year worldwide. During the past 30 years, prognosis of breast cancer patients has improved substantially, with 5‐year survival now around 90% in many countries, due partly to earlier diagnosis and greater use of adjuvant therapies.[1](#jah32266-bib-0001){ref-type="ref"} Although radiotherapy for early breast cancer can reduce the risk of death from the disease several years later, it usually involves some irradiation of the heart, and therefore, much uncertainty still remains regarding the long‐term cardiac effect from breast cancer radiotherapy.[2](#jah32266-bib-0002){ref-type="ref"}

The US SEER (Surveillance Epidemiology and End Results) cancer registries have reported increased risk of cardiovascular death after radiotherapy for breast cancer during the first 2 decades.[3](#jah32266-bib-0003){ref-type="ref"} A population‐based case‐control study by Darby et al suggested that exposure of the heart to ionizing radiation during breast cancer radiotherapy increased the subsequent rate of ischemic heart disease in a dose‐response relationship.[4](#jah32266-bib-0004){ref-type="ref"} In contrast, a population‐based cohort study by Boekel et al did not find an increased risk of cardiovascular disease after radiotherapy for ductal carcinoma in situ.[5](#jah32266-bib-0005){ref-type="ref"} The discordant findings may be explained, in part, by differences in the duration of follow‐up, disease outcomes (eg, coronary heart disease or cardiac death), radiation schemes (eg, older or modern radiotherapy techniques), and radiotherapy fields.

If the relationship between cardiac radiation exposure and the long‐term risk of heart disease were known, then physicians should weigh the likely long‐term benefit of radiotherapy on the breast cancer and the likely long‐term risk of radiation‐induced heart disease and tailor the treatment accordingly. Therefore, we conducted a meta‐analysis with the following aims: (1) to investigate cardiovascular risk in breast cancer patients with left‐sided irradiation or with right‐sided irradiation; (2) to investigate cardiovascular risk in breast cancer patients with or without radiotherapy; (3) to measure the relationship between breast cancer radiotherapy and cardiovascular risk according to different characteristics of the study populations, study designs, follow‐up duration, and treatment eras; and (4) to estimate absolute risk of cardiovascular disease associated with breast cancer radiotherapy in the studies included in the meta‐analysis.

Methods {#jah32266-sec-0009}
=======

Search Strategy {#jah32266-sec-0010}
---------------

We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta‐Analyses) guidelines for systematic reviews and meta‐analyses.[6](#jah32266-bib-0006){ref-type="ref"} We searched the publications listed in the electronic databases MEDLINE (source PubMed, January 1, 1966 to January 31, 2014) and EMBASE (January 1, 1980 to January 31, 2014) using the following text and key words in combination both as MeSH terms and text word "radiotherapy OR irradiation OR radiation" AND "breast cancer OR breast tumor" AND "cardiac OR cardiovascular OR heart OR coronary OR toxicity OR morbidity OR mortality OR death." We searched articles published in any language and scrutinized references from these studies to identify other relevant studies. Ethical approval was not needed.

Outcomes {#jah32266-sec-0011}
--------

The primary study end points were coronary heart disease (defined as diagnosis of ischemic heart disease, acute coronary syndrome, acute myocardial infarction, or death from ischemic heart disease) and cardiac mortality identified using the death registry or validated with medical records. In addition, we included an analysis of death from any cause to examine whether the risk for cardiac death would offset the survival benefit by radiotherapy. We also analyzed the end point of heart failure, arrhythmia, and valvular heart disease that may be associated with cardiovascular toxicity by radiotherapy.

Study Selection {#jah32266-sec-0012}
---------------

To minimize differences between studies, we imposed the following methodological restrictions for the inclusion criteria. (1) We used studies that contained the minimum information necessary to estimate the relative risk (RR) associated with radiotherapy and a corresponding measure of uncertainty (ie, 95%CI, standard error, variance, or *P* value of the significance of the estimate). (2) We included cohort studies, case‐control studies, and randomized controlled trials published as original articles; case reports, ecological, and prevalence studies were excluded. (3) We considered studies that were independent. Once full articles were retrieved, studies were further excluded if there was an overlap in patients with another study within the same analysis (in which case, the larger sample size of the 2 studies was selected). If some patients had been included in another study with different analysis (eg, coronary heart disease and cardiac mortality), they would be included once in 1 given analysis. Consequently, there was no overlap in patients included in our meta‐analyses.

Data Abstraction and Quality Assessment {#jah32266-sec-0013}
---------------------------------------

Two authors (Y.‐J.C. and X.‐Y.N.) extracted the data, and 1 author (C.‐C.J.) independently double‐checked the available data. The following data were extracted from each study: first author\'s name, publication year, geographical location, mean age, sample size, study design, sampling framework, study population, study end points, number of events, duration of follow‐up, treatment era, and the relative risks and associated measure of variance for all categories of outcomes. When available, we used the most comprehensively adjusted risk estimates. Percentage agreement between the 2 authors on the quality review ranged from 90% to 100%. Any disagreements were resolved by consensus.

To determine the quality of the included studies, we used the Modified Jadad Score for the randomized control trials and the Newcastle‐Ottawa scale for the observational studies. Y.‐J.C. and X.‐Y.N. developed the evaluation criteria (Tables [S1](#jah32266-sup-0001){ref-type="supplementary-material"} through [S3](#jah32266-sup-0001){ref-type="supplementary-material"}). The score ranged from 0 to 9 points for cohort and case‐control studies and from 0 to 5 points for randomized controlled studies, with a higher score indicating higher study quality.

Statistical Analysis {#jah32266-sec-0014}
--------------------

The RR was used as a measure of the association between breast cancer radiotherapy and cardiovascular risk. For case‐control studies, the odds ratio was used as an estimate of the RR because cardiovascular events are sufficiently rare.[7](#jah32266-bib-0007){ref-type="ref"}

We assessed the heterogeneity across studies by the Cochran test and by calculating the I^2^ statistic (describing the percentage of total variation across trials that was due to heterogeneity rather than chance), applying the following interpretation for I^2^: \<50%=low heterogeneity; 50% to 75%=moderate heterogeneity; \>75%=high heterogeneity.[8](#jah32266-bib-0008){ref-type="ref"}, [9](#jah32266-bib-0009){ref-type="ref"} We pooled RRs from individual trials according to the method of DerSimonian and Laird for random effects. Subgroup analyses and meta‐regression models were carried out to investigate potential sources of between‐study heterogeneity. We calculated absolute difference in event rate with radiotherapy as {(RR−1)×I~0~}, where RR indicates pooled RRs and I~0~ was the cumulative event rate per 100 000 patient‐years of follow‐up for the reference population. On the basis of population‐based cohort studies, I~0~ was estimated by weighting by the sample size of each study.

Small study bias, consistent with publication bias, was assessed with funnel plot, by the Begg adjusted rank correlation test and by the Egger regression asymmetry test.[8](#jah32266-bib-0008){ref-type="ref"}, [9](#jah32266-bib-0009){ref-type="ref"} We also performed the Duval and Tweedie nonparametric "trim and fill" procedure to further assess the possible effect of publication bias in our meta‐analysis.[10](#jah32266-bib-0010){ref-type="ref"} All *P* values are 2‐sided. Results were considered to be statistically significant at a *P* value of less than 0.05. Statistical analysis was performed with the use of Stata software, version 12.0 (StataCorp, College Station, TX).

Results {#jah32266-sec-0015}
=======

Study Selection {#jah32266-sec-0016}
---------------

Our literature search identified 2523 potentially relevant studies as shown in the flow diagram. Of these, 281 articles were considered of interest, and full text was retrieved for detailed evaluation. An additional 242 studies were excluded due to overlap of patients or no relevant outcomes, and finally, 39 studies were included in the meta‐analysis (Figure [S1](#jah32266-sup-0001){ref-type="supplementary-material"}).

Study Characteristics {#jah32266-sec-0017}
---------------------

A total of 1 191 371 individuals were enrolled in 39 eligible studies, including 11 randomized controlled trials,[11](#jah32266-bib-0011){ref-type="ref"}, [12](#jah32266-bib-0012){ref-type="ref"}, [13](#jah32266-bib-0013){ref-type="ref"}, [14](#jah32266-bib-0014){ref-type="ref"}, [15](#jah32266-bib-0015){ref-type="ref"}, [16](#jah32266-bib-0016){ref-type="ref"}, [17](#jah32266-bib-0017){ref-type="ref"}, [18](#jah32266-bib-0018){ref-type="ref"}, [19](#jah32266-bib-0019){ref-type="ref"}, [20](#jah32266-bib-0020){ref-type="ref"}, [21](#jah32266-bib-0021){ref-type="ref"} 13 cancer registry database studies,[5](#jah32266-bib-0005){ref-type="ref"}, [22](#jah32266-bib-0022){ref-type="ref"}, [23](#jah32266-bib-0023){ref-type="ref"}, [24](#jah32266-bib-0024){ref-type="ref"}, [25](#jah32266-bib-0025){ref-type="ref"}, [26](#jah32266-bib-0026){ref-type="ref"}, [27](#jah32266-bib-0027){ref-type="ref"}, [28](#jah32266-bib-0028){ref-type="ref"}, [29](#jah32266-bib-0029){ref-type="ref"}, [30](#jah32266-bib-0030){ref-type="ref"}, [31](#jah32266-bib-0031){ref-type="ref"}, [32](#jah32266-bib-0032){ref-type="ref"}, [33](#jah32266-bib-0033){ref-type="ref"} and 15 single‐ and multi‐institutional trials.[34](#jah32266-bib-0034){ref-type="ref"}, [35](#jah32266-bib-0035){ref-type="ref"}, [36](#jah32266-bib-0036){ref-type="ref"}, [37](#jah32266-bib-0037){ref-type="ref"}, [38](#jah32266-bib-0038){ref-type="ref"}, [39](#jah32266-bib-0039){ref-type="ref"}, [40](#jah32266-bib-0040){ref-type="ref"}, [41](#jah32266-bib-0041){ref-type="ref"}, [42](#jah32266-bib-0042){ref-type="ref"}, [43](#jah32266-bib-0043){ref-type="ref"}, [44](#jah32266-bib-0044){ref-type="ref"}, [45](#jah32266-bib-0045){ref-type="ref"}, [46](#jah32266-bib-0046){ref-type="ref"}, [47](#jah32266-bib-0047){ref-type="ref"}, [48](#jah32266-bib-0048){ref-type="ref"} Twenty‐two studies were based in Europe, 13 in North America, 1 in Australia and 3 were multinational; 16 studies recruited participants from population registers, and 23 were hospital based (Table [S1](#jah32266-sup-0001){ref-type="supplementary-material"}). The years of patient irradiation ranged from 1949 to 2008, with the study results typically published between 1985 and 2014 and a median follow‐up of 1 to 28 years. Ten trials compared patients who had received radiation therapy with those who had not received radiation therapy; 14 trials compared left‐sided breast cancer radiation therapy and right‐sided breast cancer radiation therapy, and 15 trials compared both. The sizes of the studies ranged from 41 to 558 871, with the 9 largest studies recruiting over 10 000 patients. Of the 28 observational studies, the scores of the Newcastle‐Ottawa scale quality assessment ranged from 5 to 9, and 14 studies had scores of 7 or higher. The methodological quality of the 11 randomized controlled trials was generally good, with Modified Jadad Score of 3 or higher in all the studies (Tables [S2](#jah32266-sup-0001){ref-type="supplementary-material"} through [S4](#jah32266-sup-0001){ref-type="supplementary-material"}).

Cardiovascular Morbidity and Mortality in Patients With Left‐Sided Radiotherapy or With Right‐Sided Radiotherapy {#jah32266-sec-0018}
----------------------------------------------------------------------------------------------------------------

### Coronary Heart Disease {#jah32266-sec-0019}

Twenty studies were included for the outcome of coronary heart disease, involving 233 761 participants and 2723 events. In a comparison of women receiving left‐sided radiotherapy with those receiving right‐sided radiotherapy, the overall RR of coronary heart disease was 1.29 (95%CI 1.13‐1.48; *P*\<0.001), with low between‐study heterogeneity (I^2^ 42.87%, 95%CI 3.01‐66.35%, *P*=0.02) (Figure [1](#jah32266-fig-0001){ref-type="fig"}). Visual inspection of the Begg funnel plot did not identify substantial asymmetry, and the Begg rank correlation test was not statistically significant (*P*=0.23) (Figure [S2](#jah32266-sup-0001){ref-type="supplementary-material"}). However, the Egger linear regression test indicated a possibility of publication bias (*P*=0.02). With the trim‐and‐fill approach, the imputed estimate (RR 1.26, 95%CI 1.09‐1.46, *P*=0.002) was similar to that in the main analysis, indicating that results are unlikely to be explained by publication bias. In a sensitivity analysis that included only the 11 studies that used myocardial infarction or death due to coronary heart disease as the outcome of interest, the pooled RR was 1.34 (95%CI 1.20‐1.50), with no evidence of significant heterogeneity (I^2^ 0%, 95%CI 0‐60.23%, *P*=0.49) (Figure [S3](#jah32266-sup-0001){ref-type="supplementary-material"}).

![Forest plot for risk of coronary heart disease and cardiac mortality in patients with left‐sided radiotherapy vs those with right‐sided radiotherapy. The size of each square is proportional to the study\'s weight (inverse of variance). I^2^ indicates variation in RR attributable to heterogeneity; RR, relative risk.](JAH3-6-e005633-g001){#jah32266-fig-0001}

In the stratified analyses little of the heterogeneity was explained by study type (*P*=0.65), breast cancer staging (*P*=0.69), follow‐up duration (*P*=1.00), age at breast cancer diagnosis (*P*=0.11), number of patients (*P*=0.47), source of patients (*P*=0.83), whether risk profiles were adjusted (*P*=0.83), or whether adjuvant chemotherapy was administered (*P*=0.38). Significant heterogeneity between pooled analyses was noted for studies published before 2010 compared with those published after 2010 (RR 1.42, 95%CI 1.19‐1.69 versus 1.14, 95%CI 1.04‐1.25, *P*=0.03), studies in which cases were validated with medical record compared with studies in which they were not (RR 1.66, 95%CI 1.09‐2.54 versus 1.26, 95%CI 1.10‐1.44, *P*=0.03), and breast cancer diagnosed before 1980 compared with breast cancer diagnosed after 1980 (RR 1.32, 95%CI 1.09‐1.44 versus 1.16, 95%CI 1.01‐1.33, *P*=0.04). The RRs for coronary heart disease in women with left‐sided versus right‐sided radiotherapy, according to the number of years since diagnosis of breast cancer, were as follows: 0 to 4 years, 1.14 (95%CI 0.95‐1.36); 5 to 9 years, 1.17 (95%CI 1.04‐1.32); 10 to 14 years, 1.93 (95%CI 1.13‐3.30); 15 to 20 years, 1.39 (95%CI 1.08‐1.79) (Table [1](#jah32266-tbl-0001){ref-type="table-wrap"}).

###### 

Stratified Analysis and Heterogeneity Analysis of Relative Risks of Coronary Heart Disease and Cardiac Mortality in Left‐Sided Versus Right‐Sided Radiotherapy

  Factors Stratified                    Coronary Heart Disease   Cardiac Mortality                                                                      
  ------------------------------------- ------------------------ ------------------- ------------------- -------- --------- -------- ------------------ ---------
  All studies                           233 761                  2723                1.29 (1.13‐1.48)             239 434   11 810   1.22 (1.08‐1.37)   
  Types of studies                                                                                                                                      
   Observational studies                231 876                  2666                1.30 (1.13‐1.48)    0.65     232 006   11 479   1.16 (1.01‐1.32)   0.10
   RCT                                  1885                     57                  2.07 (0.28‐15.05)            7428      331      1.44 (1.18‐1.76)   
  Location                                                                                                                                              
   Europe                               27 024                   1668                1.14 (1.01‐1.29)    0.01     115 344   8005     1.14 (1.01‐1.29)   0.65
   North America                        10 921                   409                 1.65 (1.16‐2.34)             6805      562      1.37 (0.88‐2.13)   
  Publication year                                                                                                                                      
   \<2010                               223 687                  1572                1.42 (1.19‐1.69)    0.03     192 265   9925     1.34 (1.11‐1.62)   0.08
   ≧2010                                10 074                   1151                1.14 (1.04‐1.25)             47 169    1885     1.03 (0.93‐1.14)   
  Breast cancer staging                                                                                                                                 
   0 to II                              7143                     300                 1.38 (0.90‐2.11)    0.69     36 152    866      1.40 (1.22‐1.61)   \<0.001
   I to IV                              226 618                  2423                1.27 (1.12‐1.43)             131 838   8648     1.07 (0.97‐1.17)   
  Surgery                                                                                                                                               
   Breast‐conserving                    6130                     291                 1.80 (1.21‐2.66)    0\. 02   98 148    7921     1.12 (1.00‐1.25)   0.58
   Mastectomy                           7414                     331                 1.05 (0.77‐1.43)             68 621    2922     1.30 (1.03‐1.64)   
   Breast‐conserving or mastectomy      220 217                  2101                1.24 (1.09‐1.42)             23 774    1207     1.08 (0.88‐1.33)   
  Follow‐up, y                                                                                                                                          
   \<20                                 15 797                   483                 1.35 (0.93‐1.94)    1.00     47 169    1885     1.18 (0.93‐1.52)   0.52
   ≧20                                  217 892                  2207                1.28 (1.14‐1.44)             192 265   9925     1.25 (1.08‐1.45)   
  Adjusted for risk profiles                                                                                                                            
   Yes                                  221 489                  1440                1.30 (1.12‐1.53)    0.83     232 387   11 485   1.35 (1.08‐1.69)   0.33
   No                                   12 272                   1283                1.36 (1.03‐1.78)             7047      325      1.18 (1.03‐1.35)   
  Adjuvant chemotherapy                                                                                                                                 
   Yes                                  214 908                  2237                1.35 (1.12‐1.63)    0.38     159 218   4986     1.13 (0.92‐1.39)   0.30
   No                                   18 853                   486                 1.20 (1.01‐1.42)             80 216    6824     1.32 (1.08‐1.60)   
  Patients, n                                                                                                                                           
   \<2000                               8123                     385                 1.42 (1.02‐1.97)    0.47     8698      335      1.41 (1.08‐1.84)   0.11
   ≧2000                                225 638                  2338                1.25 (1.10‐1.43)             230 736   11 475   1.15 (1.01‐1.30)   
  Age, y                                                                                                                                                
   \<55                                 9659                     498                 1.23 (1.09‐1.38)    0.11     3307      109      1.49 (1.01‐2.19)   0.21
   ≧55                                  224 102                  2225                1.60 (1.10‐2.34)             229 381   11 460   1.13 (0.99‐1.28)   
  Source of patients                                                                                                                                    
   Population based                     227 067                  2467                1.28 (1.09‐1.50)    0.83     176 405   5621     1.26 (1.07‐1.48)   0.49
   Hospital based                       6694                     256                 1.33 (0.97‐1.83)             63 029    6189     1.16 (0.92‐1.48)   
  Case validation                                                                                                                                       
   Yes                                  6640                     1166                1.66 (1.09‐2.54)    0.03     9012      323      1.56 (1.28‐1.91)   0.01
   No                                   227 121                  1557                1.26 (1.10‐1.44)             230 422   11 487   1.12 (1.00‐1.27)   
  Period of breast cancer diagnosis                                                                                                                     
   \<1980                               84 335                   5046                1.32 (1.21‐1.44)    0.04     81 730    10 855   1.45 (1.14‐1.89)   0.04
   ≧1980                                88 680                   3455                1.16 (1.01‐1.33)             143 606   6680     1.15 (0.92‐1.44)   
  Years since breast cancer diagnosis                                                                                                                   
   1 to 4                               308 190                  1534                1.14 (0.95‐1.36)    NA       173 683   4794     1.02 (0.96‐1.08)   NA
   5 to 9                               303 821                  1445                1.17 (1.04‐1.32)             166 014   2801     1.05 (0.97‐1.14)   
   10 to 14                             302 376                  1250                1.93 (1.13‐3.30)             164 387   1125     1.26 (1.11‐1.44)   
   15 to 20                             285 165                  736                 1.39 (1.08‐1.79)             124 462   929      1.44 (1.14‐1.82)   

RCT indicates randomized controlled trial; RR, relative risk.

*P*‐values test homogeneity between strata.

John Wiley & Sons, Ltd

In a sensitivity analysis of women who had not been irradiated, the relative risk of coronary heart disease, left versus right tumor laterality, was close to 1 (1.02, 95%CI 0.95‐1.10, *P*=0.60) (Figure [S4](#jah32266-sup-0001){ref-type="supplementary-material"}). Using the average event rate in women receiving right‐sided radiotherapy from included studies and the summary estimates obtained from all studies combined, left‐sided breast cancer radiotherapy was associated with an absolute risk increase of 66.8 (95%CI 37.6‐102.5) cases of coronary heart disease per 100 000 person‐years.

### Cardiac Mortality {#jah32266-sec-0020}

Eighteen studies with data of 239 434 individuals and at least 11 810 events reported risk estimates for cardiac mortality. Overall, compared with women who had received radiotherapy for a right‐sided tumor, women who had received radiotherapy for a left‐sided breast cancer experienced a significantly increased risk for cardiac mortality (RR 1.22, 95%CI 1.08‐1.37, *P*=0.002). There was evidence of moderate heterogeneity of RRs across these studies (I^2^ 66.26%, 95%CI 44.60% to 79.45%, *P\<*0.001) (Figure [1](#jah32266-fig-0001){ref-type="fig"}). Neither funnel plots nor Egger and Begg tests showed evidence of publication bias (Egger, *P*=0.88; Begg, *P*=0.47) (Figure [S2](#jah32266-sup-0001){ref-type="supplementary-material"}).

To explore the study heterogeneity, we performed analyses subdivided by a number of key study characteristics and clinical factors. Study type, geographical area, surgery type, publication year, follow‐up duration, age at breast cancer diagnosis, number of patients, source of patients, whether risk profiles were adjusted, or whether adjuvant chemotherapy was administered were not significant sources of heterogeneity. However, we found higher risks in studies in which cases were validated with medical records than in studies in which they were not (RR 1.56, 95%CI 1.28‐1.91 versus 1.12, 95%CI 1.00‐1.27, *P*=0.01). In addition, breast cancer diagnosis period also seemed to be associated with the results (RR 1.45, 95%CI 1.14‐1.89 for women diagnosed before 1980 and irradiated versus 1.15, 95%CI 0.92‐1.44 for women diagnosed after 1980 and irradiated; *P*=0.04). The RRs for cardiac mortality, left versus right tumor laterality, increased steeply with time since diagnosis of breast cancer: 0 to 4 years, 1.02 (95%CI 0.96‐1.08); 5 to 9 years, 1.05 (95%CI 0.97‐1.14); 10 to 14 years, 1.26 (95%CI 1.11‐1.44); 15 to 20 years, 1.44 (95%CI 1.14‐1.82) (Table [1](#jah32266-tbl-0001){ref-type="table-wrap"}).

For women not given radiotherapy, there was little evidence of an association between breast cancer laterality and subsequent cardiac mortality (1.02, 95%CI 0.98‐1.06, *P*=0.28) (Figure [S5](#jah32266-sup-0001){ref-type="supplementary-material"}). Compared with women receiving right‐sided radiotherapy, women with left‐sided radiotherapy experienced an absolute risk increase of 73.9 (95%CI 41.6‐113.9) cases of cardiac death per 100 000 person‐years.

### Secondary End Points {#jah32266-sec-0021}

For death from any cause, 13 studies were included, reporting 96 725 events among 534 419 participants. Left‐sided radiotherapy was associated with a significantly increased risk of death from any cause compared with right‐sided radiotherapy (RR 1.05, 95%CI 1.01‐1.10, *P*=0.02) (Figure [S6](#jah32266-sup-0001){ref-type="supplementary-material"}). We also had additional analysis of other end points in relation to coronary heart disease. Similarly, women with left‐sided radiotherapy, as compared with the reference group, appeared to experience increased risk of death from coronary heart disease (RR 1.23, 95%CI 1.07‐1.41, *P*=0.004), death from myocardial infarction (RR 1.35, 95%CI 1.12‐1.63, *P*=0.002), and myocardial infarction (RR 1.21, 95%CI 1.05‐1.39, *P*=0.007) (Table [2](#jah32266-tbl-0002){ref-type="table-wrap"}). However, left‐sided radiotherapy did not seem to be associated with risks of heart failure, arrhythmia, and valvular heart disease (Table [2](#jah32266-tbl-0002){ref-type="table-wrap"}).

###### 

Summary Estimates of Relative Risks of Other Cardiovascular Outcomes Associated With Radiotherapy for Breast Cancer

  End Points                                            No. of Studies   No. of Participants   No. of Events   RR (95%CI)          I^2^ (95%CI) [a](#jah32266-note-0005){ref-type="fn"}   *P* Value[b](#jah32266-note-0006){ref-type="fn"}
  ----------------------------------------------------- ---------------- --------------------- --------------- ------------------- ------------------------------------------------------ --------------------------------------------------
  Left‐sided radiotherapy vs right‐sided radiotherapy                                                                                                                                     
   Death from any cause                                 13               534 419               96 725          1.05 (1.01‐1.10)    57.23 (20.69‐76.94)                                    0.01
   Death from coronary heart disease                    13               252 654               5103            1.23 (1.07‐1.41)    54.41 (14.75‐75.62)                                    0.01
   Death from myocardial infarction                     10               221 515               4476            1.35 (1.12‐1.63)    49.61 (0‐75.59)                                        0.04
   Myocardial infarction                                14               126 998               5337            1.21 (1.05‐1.39)    47.75 (2.93‐71.87)                                     0.02
   Heart failure                                        7                59 157                2570            1.00 (0.91‐1.12)    7.69 (0‐73.05)                                         0.37
   Arrhythmia                                           7                58 630                2645            1.00 (0.92‐1.07)    0 (0‐70.81)                                            0.68
   Valvular heart disease                               4                57 699                640             1.22 (0.91‐1.66)    35.79 (0‐75.96)                                        0.18
  Radiotherapy vs no radiotherapy                                                                                                                                                         
   Death from any cause                                 8                50 346                8388            1.01 (0.85‐1.20)    90.33 (83.35‐94.38)                                    \<0.001
   Death from coronary heart disease                    8                34 083                1152            1.40 (1.12‐1.75)    60.47 (14.16‐81.80)                                    0.01
   Death from myocardial infarction                     4                5628                  53              1.84 (0.56‐6.04)    78.93 (43.61‐92.13)                                    0.003
   Myocardial infarction                                9                69 358                3278            1.33 (1.002‐1.77)   77.95 (58.27‐88.35)                                    \<0.001
   Heart failure                                        9                70 354                11 235          1.17 (0.90‐1.51)    74.55 (50.71‐86.86)                                    \<0.001
   Arrhythmia                                           3                15 749                252             1.04 (0.69‐1.58)    30.80 (0‐92.80)                                        0.24
   Valvular heart disease                               4                20 580                239             1.97 (0.84‐4.62)    61.04 (0‐86.96)                                        0.05

RR indicates relative risk.

I^2^ is a measure of the variation in RR attributable to heterogeneity.

*P* value for I^2^.

John Wiley & Sons, Ltd

Cardiovascular Morbidity and Mortality in Patients With Radiotherapy or Without Radiotherapy {#jah32266-sec-0022}
--------------------------------------------------------------------------------------------

### Coronary Heart Disease {#jah32266-sec-0023}

From 17 studies analyzed, there were 10 640 cases of coronary heart disease among 155 236 participants. In a comparison of women who received radiotherapy with those who received no radiotherapy, the RR for coronary heart disease was 1.30 (95%CI 1.13‐1.49, *P*\<0.001), with moderate heterogeneity (I^2^ 72.89%, 95%CI 56.06% to 83.28%, *P*\<0.001) (Figure [2](#jah32266-fig-0002){ref-type="fig"}). Visual inspection of the Begg funnel plot revealed asymmetry (*P*\<0.001). This raises the possibility of publication bias, although neither the Begg nor the Egger test was statistically significant (Begg, *P*=0.48; Egger, *P*=0.22) (Figure [S2](#jah32266-sup-0001){ref-type="supplementary-material"}). Because of this, we undertook a sensitivity analysis using the trim‐and‐fill method, and the pooled analysis incorporating the hypothetical studies continued to show a statistically significant association between radiotherapy and risk of coronary heart disease (RR 1.18, 95%CI 1.03‐1.36, *P*=0.01). Further analysis of 9 studies that used myocardial infarction or death from coronary heart disease as the end point yielded similar results (RR 1.39, 95%CI 1.10‐1.76, *P*=0.01) (Figure [S7](#jah32266-sup-0001){ref-type="supplementary-material"}).

![Forest plot for risk of coronary heart disease and cardiac mortality in patients with radiotherapy vs those without radiotherapy. The size of each square is proportional to the study\'s weight (inverse of variance). I^2^ indicates variation in RR attributable to heterogeneity; RR, relative risk.](JAH3-6-e005633-g002){#jah32266-fig-0002}

The finding of increased risk of coronary heart disease in patients who received radiotherapy was consistently found in all of the stratified analyses. Study quality characteristics did not seem to markedly influence the results, although a stronger association was observed for studies in which cases of coronary heart disease were confirmed by laboratory examination or medical record (*P*=0.004). Notably, although treatment era seemed to be associated with the results, patients diagnosed after 1980 with modern radiotherapy techniques still experienced increased risk of coronary heart disease compared with those without radiotherapy (RR 1.21, 95%CI 1.01‐1.37, *P*=0.04). The risk increase started within the first 5 years and continued into the third decade after radiotherapy: the RRs were 1.40 (95%CI 1.12‐1.74) for 0 to 4 years, 1.70 (95%CI 1.18‐2.45) for 5 to 9 years, 1.79 (95%CI 1.08‐2.97) for 10 to 14 years, 1.23 (95%CI 1.02‐1.48) for 15 to 19 years, and 1.88 (95%CI 1.08‐3.27) for 20 years or more (Table [3](#jah32266-tbl-0003){ref-type="table-wrap"}). From studies that reported information on person‐years in patients with radiotherapy and without radiotherapy, we could calculate that women with radiotherapy experienced an absolute risk increase of 76.4 (95%CI 36.8‐130.5) cases of coronary heart disease per 100 000 person‐years.

###### 

Stratified Analysis and Heterogeneity Analysis of Relative Risks of Cardiac Death and Coronary Heart Disease in Radiotherapy Versus No Radiotherapy

  Factors Stratified                    Coronary Heart Disease   Cardiac Mortality                                                                  
  ------------------------------------- ------------------------ ------------------- ------------------ ------- --------- ------ ------------------ ------
  All studies                           155 236                  10 640              1.30 (1.13‐1.49)           137 074   5367   1.38 (1.18‐1.62)   
  Types of studies                                                                                                                                  
   Observational studies                149 104                  10 490              1.26 (1.11‐1.44)   0.31    98 245    3948   1.33 (1.01‐1.75)   0.74
   RCT                                  6132                     150                 2.63 (1.05‐6.58)           38 829    1383   1.43 (1.17‐1.75)   
  Location                                                                                                                                          
   Europe                               106 017                  6142                1.29 (1.13‐1.17)   0.02    113 719   4553   1.53 (1.31‐1.79)   0.01
   North America                        866                      142                 2.78 (1.20‐6.40)           3180      55     0.44 (0.25‐0.76)   
  Publication year                                                                                                                                  
   \<2010                               135 743                  9033                1.32 (1.06‐1.63)   0.86    47 575    1638   1.43 (1.22‐1.67)   0.68
   ≧2010                                19 493                   1607                1.20 (1.10‐1.31)           89 499    3929   1.30 (0.89‐1.88)   
  Breast cancer staging                                                                                                                             
   0 to II                              67 136                   3670                1.21 (0.69‐2.11)   0.43    41 332    1253   1.36 (1.01‐1.67)   0.95
   I to IV                              88 100                   6970                1.32 (1.14‐1.53)           95 742    4114   1.39 (1.07‐1.82)   
  Surgery                                                                                                                                           
   Breast‐conserving                    54 617                   3369                0.60 (0.35‐1.04)   0.20    ···       ···    ···                
   Mastectomy                           10 681                   735                 1.47 (1.02‐2.12)           11 319    472    1.59 (1.31‐1.94)   0.10
   Breast‐conserving or mastectomy      89 938                   6536                1.31 (1.13‐1.52)           125 755   4895   1.21 (0.97‐1.52)   
  Follow‐up, year                                                                                                                                   
   \<20                                 72 870                   4071                1.20 (0.88‐1.63)   0.43    21 144    471    1.01 (0.71‐1.45)   0.02
   ≧20                                  81 847                   6430                1.32 (1.11‐1.57)           115 807   4888   1.51 (1.29‐1.77)   
  Adjusted for risk profiles                                                                                                                        
   Yes                                  148 875                  10 484              1.26 (1.10‐1.44)   0.31    110 750   4688   1.43 (1.22‐1.66)   0.50
   No                                   6361                     156                 2.10 (1.12‐3.95)           26 324    679    1.28 (0.91‐1.80)   
  Adjuvant chemotherapy                                                                                                                             
   Yes                                  116 751                  9782                1.23 (1.03‐1.46)   0.17    104 137   4399   1.25 (0.93‐1.68)   0.40
   No                                   38 485                   858                 1.42 (1.24‐1.62)           32 937    968    1.50 (1.33‐1.71)   
  Patients, n                                                                                                                                       
   \<2000                               4634                     233                 2.04 (1.36‐3.07)   0.10    8899      358    1.26 (0.83‐1.92)   0.47
   ≧2000                                150 602                  10 407              1.20 (1.05‐1.37)           128 175   5009   1.43 (1.24‐1.66)   
  Age, y                                                                                                                                            
   \<55                                 8011                     860                 2.00 (1.21‐3.30)   0.06    9363      272    1.11 (0.33‐3.80)   0.81
   ≧55                                  144 511                  9708                1.19 (1.03‐1.37)           110 634   4551   1.31 (1.04‐1.64)   
  Source of patients                                                                                                                                
   Population based                     147 915                  10 446              1.25 (1.09‐1.44)   0.34    108 451   4364   1.14 (0.88‐1.48)   0.09
   Hospital based                       7321                     194                 1.83 (1.12‐3.06)           28 623    1003   1.56 (1.29‐1.89)   
  Case validation                                                                                                                                   
   Yes                                  5231                     449                 2.26 (1.43‐3.57)   0.004   24 142    726    1.68 (1.23‐2.27)   0.03
   No                                   150 005                  10 191              1.20 (1.05‐1.36)           122 932   4641   1.25 (1.05‐1.50)   
  Period of breast cancer diagnosis                                                                                                                 
   \<1980                               9913                     882                 1.52 (1.29‐1.79)   0.02    22 493    843    1.58 (1.39‐1.80)   0.04
   ≧1980                                70 699                   6053                1.21 (1.01‐1.37)           33 084    1060   1.27 (0.82‐1.97)   
  Years since breast cancer diagnosis                                                                                                               
   1 to 4                               15 944                   537                 1.40 (1.12‐1.74)   NA      22 211    212    1.04 (0.51‐2.12)   NA
   5 to 9                               7596                     408                 1.70 (1.18‐2.45)           11 672    149    1.17 (0.55‐2.48)   
   10 to 14                             9066                     614                 1.79 (1.08‐2.97)           10 332    210    1.41 (1.04‐1.92)   
   15 to 19                             26 800                   844                 1.23 (1.02‐1.48)           14 578    375    1.63 (1.21‐2.21)   
   \>20                                 4612                     259                 1.88 (1.08‐3.27)           13 324    1128   1.59 (1.33‐1.91)   

RCT indicates randomized controlled trial; RR, relative risk.

*P*‐Values test homogeneity between strata.

John Wiley & Sons, Ltd

### Cardiac Mortality {#jah32266-sec-0024}

For the end point of cardiac mortality in women with radiotherapy versus no radiotherapy, 16 studies involving 137 074 patients and 5367 events were included. Compared with women who had not received radiotherapy, those who had received radiotherapy had a 1.38‐fold (95%CI 1.18‐1.62, *P*\<0.001) higher risk of cardiac mortality (Figure [2](#jah32266-fig-0002){ref-type="fig"}). Although there was moderate heterogeneity among the available studies (I^2^ 71.01%, 95%CI 51.87% to 82.54%, *P*\<0.001), the Begg and Egger tests indicated no evidence of publication bias (Begg, *P*=0.96; Egger, *P*=0.12) (Figure [S2](#jah32266-sup-0001){ref-type="supplementary-material"}).

When we evaluated prespecified potential sources of heterogeneity, the major sources were follow‐up duration, case validation, and breast cancer diagnosis period. The RRs were higher in studies with follow‐up duration of more than 20 years than in those with follow‐up duration of less than 20 years (RR 1.51, 95%CI 1.29‐1.77, versus 1.01, 95%CI 0.71‐1.45, *P*=0.02), studies with case validation than those without case validation (RR 1.68, 95%CI 1.23‐2.27, versus 1.25, 95%CI 1.05‐1.50, *P*=0.03), and breast cancer diagnosed before 1980 than that diagnosed after 1980 (RR 1.58, 95%CI 1.39‐1.80, versus 1.27, 95%CI 0.82‐1.97, *P*=0.04). The RRs of cardiac mortality were 1.04 (95%CI 0.51‐2.12) during 0 to 4 years after primary diagnosis, 1.17 (95%CI 0.55‐2.48) during 5 to 9 years, 1.41 (95%CI 1.04‐1.92) during 10 to 14 years, 1.63 (95%CI 1.21‐2.21) during 15 to 19 years, and 1.59 (95%CI 1.33‐1.91) after 20 years (Table [3](#jah32266-tbl-0003){ref-type="table-wrap"}). The absolute excess risk of cardiac mortality for patients receiving radiotherapy, as compared with those who received no radiotherapy, was 125.5 (95%CI 98.8‐157.9) cases per 100 000 person‐years.

### Secondary End Points {#jah32266-sec-0025}

For the end points associated with coronary heart disease, elevated RRs were observed for death from coronary heart disease (RR 1.40, 95%CI 1.12‐1.75, *P*=0.003) and myocardial infarction (RR 1.33, 95%CI 1.002‐1.77, *P*=0.049). Analysis of 4 studies involving 5628 patients and 53 events showed a statistically nonsignificant 1.84‐fold increased risk for death from myocardial infarction. In addition, we found no significant association between radiotherapy and risk of death from any cause, heart failure, arrhythmia, and valvular heart disease (Table [2](#jah32266-tbl-0002){ref-type="table-wrap"}).

Discussion {#jah32266-sec-0026}
==========

The present meta‐analysis, involving 1 191 371 patients from 39 studies, has assessed the strength and consistency of associations between breast cancer radiotherapy and subsequent risk of cardiovascular disease. We have shown that in women diagnosed with breast cancer, coronary heart disease and cardiac mortality were increased in the comparison of patients with left‐sided radiotherapy and those with right‐sided radiotherapy, as well as in the comparison of patients with radiotherapy and those without radiotherapy. In subgroup analyses the increase in risk with radiotherapy seemed to be driven by a stronger association among studies in which the cases were validated with medical records and breast cancer was diagnosed before 1980. The increase of risk started within the first decade for coronary heart disease and from the second decade for cardiac mortality and continued into the third decade after radiotherapy.

Previous studies have identified that atomic bomb survivors and patients given radiotherapy for peptic ulcer disease had dose‐related increases in late cardiac morbidity and mortality, whereas conflicting results were reported for patients receiving radiotherapy for breast cancer.[50](#jah32266-bib-0050){ref-type="ref"}, [51](#jah32266-bib-0051){ref-type="ref"} Results from our analysis suggest that breast cancer radiotherapy is independently associated with risk of coronary heart disease and cardiac mortality. The risk magnitude appears to be less robust than those reported for well‐established major risk factors such as smoking, hypertension, diabetes mellitus, or hyperlipidemia. It is of note that lack of case validation tends to deflate the pooled risk estimate, indicating that the true magnitude of association between breast cancer radiotherapy and cardiovascular risk may be greater. In absolute terms, 76.4 excess cases of coronary heart disease and 125.5 excess cases of cardiac death occurred per 100 000 person‐years associated with radiotherapy. The absolute risk is not small, and given that postoperative radiotherapy is one of the most commonly used adjuvant therapies and that over a million women develop breast cancer annually, the total number of excess cases of coronary heart disease and cardiac death may not be negligible. In addition, our results showed that radiotherapy did not provide improvement in the overall survival, and even left‐sided radiotherapy could increase risk of death from any cause, indicating that absolute cardiovascular risk can be weighed against the probable absolute reduction in the risk of recurrence or death from breast cancer that would be achieved with radiotherapy. In spite of the clear association between radiotherapy and cardiovascular risk in breast cancer patients, the American College of Cardiology/American Heart Association guidelines do not provide specific recommendations regarding radiation‐induced coronary heart disease or cardiovascular disease.[52](#jah32266-bib-0052){ref-type="ref"}

There is 1 factor that may confound the interpretation of cardiovascular risk associated with radiotherapy in breast cancer patients. Outside the context of randomized trials, patients may have been selected for radiotherapy according to age, nature of breast cancer, and factors associated with the prognosis, and these factors can potentially produce selection biases.[27](#jah32266-bib-0027){ref-type="ref"} Therefore, simple comparisons of subsequent mortality of irradiated and unirradiated patients might not reliably reflect the real benefit and hazard of treatments. It seems unlikely, however, that the effect can be attributed completely to selection bias because some effect remains even when only coronary heart disease and cardiac mortality are considered, and the effect for heart disease is strong even during the period over 10 years after breast cancer diagnosis. Furthermore, in the randomized trials that involved less selection bias, both risks for coronary heart disease and cardiac mortality were increased in irradiated versus unirradiated patients. But outside the randomized trials, comparisons that avoid selection biases could also be performed, as breast cancer laterality plays little part in determining who should be given radiotherapy, and the cardiac radiation dose is generally greater in left‐sided than in right‐sided breast cancer.[53](#jah32266-bib-0053){ref-type="ref"}, [54](#jah32266-bib-0054){ref-type="ref"} Therefore, comparisons of cardiovascular morbidity and mortality in irradiated women with left‐sided versus right‐sided breast cancer can give a valid indication of the extent of any radiation‐related cardiac effect even though the magnitude of risk is likely to be underestimated. The consistency of the findings of increased risk of coronary heart disease and cardiac mortality in patients with left‐sided radiotherapy versus right‐sided radiotherapy as well as in patients with radiotherapy versus those without radiotherapy suggests a causal effect of radiotherapy on heart disease.

Although previous studies have indicated that radiation‐associated cardiovascular complications involved injury of pericardium, myocardium, valves, and conduction systems, our results suggest that radiation‐induced heart disease might be mainly mediated by radiation damage to the coronary arteries leading to myocardial ischemia and myocardial infarction.[55](#jah32266-bib-0055){ref-type="ref"} First, our study identified that radiotherapy was associated with an increased risk for coronary heart disease but not for heart failure, arrhythmia, and valvular heart disease. The association persists and remains statistically significant across a number of stratified analyses exploring clinical and study quality factors and also persists in the analyses of the outcomes that are less likely to be misclassified such as myocardial infarction and death from coronary heart disease. And death from coronary heart disease may account for the largest number of deaths from cardiac cause, of which the risk is also increased in association with radiotherapy. Second, there is an appropriate temporal relationship: radiotherapy preceded incidence of coronary heart disease in all studies. The risk for coronary heart disease started within the first decade, whereas risk for cardiac death started from the second decade after radiation exposure. This is consistent with existing knowledge that it may take a patient with coronary heart disease a certain period of time to develop into cardiac death. Third, contemporary radiotherapy techniques can involve substantially lower cardiac exposures than those used previously, and therefore, the decline in risk observed for the more recent treatment period provides indirect evidence of a dose‐response relationship for radiation‐induced coronary heart disease. Fourth, there is biological plausibility for causality in that radiation may lead to oxidative stress, inflammatory cell infiltration, endothelial injury, fibrosis of the intima, a prothrombotic state, and atherosclerosis in the coronary arteries and thus may contribute to an increased risk of ischemic heart disease.[55](#jah32266-bib-0055){ref-type="ref"}

Over the past few decades, improvements in radiotherapy planning have reduced cardiac radiation exposures. This situation has been achieved partly by omitting irradiation of the internal mammary chain of lymph nodes, switching from orthovoltage to megavoltage, use of respiratory gating, or blocking the heart in tangential fields.[56](#jah32266-bib-0056){ref-type="ref"} However, dosimetric studies have demonstrated that modern techniques could not eliminate cardiac exposure, and for approximately half of left‐sided patients, part of the heart still received more than 20 Gy, probably including part of the left anterior descending coronary artery.[57](#jah32266-bib-0057){ref-type="ref"} This suggests that contemporary radiotherapy techniques may still increase the risk of ischemic heart disease in a proportion of patients, consistent with our findings that risk for coronary heart disease still slightly increased for patients irradiated after 1980. Hardenberg et al also indentified that modern radiotherapy techniques were associated with defects in myocardial perfusion, abnormalities in wall motion, and declines in ejection fraction of the heart.[58](#jah32266-bib-0058){ref-type="ref"} Notably, the excess risk of cardiac death associated with breast cancer did not become clear until more than 10 years after exposure. Thus, a possible explanation for the lack of any definite hazard of cardiac death from our analysis of a subgroup of patients diagnosed after 1980 is that the follow‐up is not long enough. Therefore, care should continue to be taken to minimize cardiac exposure as much as is practical in patients undergoing radiotherapy for breast cancer.

Strengths of this meta‐analysis include the strict inclusion criteria, the large number of patients analyzed, the robustness of the findings in sensitivity analyses, and the fact that all subgroup analyses were prespecified a priori. There are several limitations to this study. First, there is heterogeneity of RRs among studies in the primary analysis. However, stratified analyses showed pooled RRs consistently greater than 1 across a number of clinical factors. Second, the funnel plot analysis showed some asymmetry, suggesting the possibility of publication bias for coronary heart disease. The trim‐and‐fill sensitivity analysis did not change the general result, suggesting that the association is not an artifact of unpublished negative studies. Third, lack of individual participant data may preclude determining the independent associations of individual variables with study outcomes. Instead, we used between‐study meta‐regressions when possible. Fourth, because radiation doses to the whole heart and to the left anterior descending coronary artery could not be obtained, direct assessment of a dose‐response relationship for radiation‐induced heart disease was not available. We therefore compared cardiovascular risk between different treatment eras as a surrogate, which might to some extent reflect the difference in the dose of radiation to the heart. Fifth, because the individual participant data were not available, we could not calculate the risk for every subcategory of coronary heart disease. We therefore used the composite end point of coronary heart disease instead, which might not be optimal but could be appropriate in assessing the cardiovascular risk associated with breast cancer radiotherapy.[59](#jah32266-bib-0059){ref-type="ref"}, [60](#jah32266-bib-0060){ref-type="ref"}, [61](#jah32266-bib-0061){ref-type="ref"}, [62](#jah32266-bib-0062){ref-type="ref"} Sixth, given that there are no best tools available for the evaluation of the methodologic quality of randomized controlled trials, we used the most widely used Jadad scoring system as a surrogate.[63](#jah32266-bib-0063){ref-type="ref"}, [64](#jah32266-bib-0064){ref-type="ref"}, [65](#jah32266-bib-0065){ref-type="ref"}

In conclusion, the results from this meta‐analysis suggest that radiotherapy for breast cancer might increase the risk of coronary heart disease as well as cardiac mortality. The increase of risk started within the first decade for coronary heart disease and from the second decade for cardiac mortality. Contemporary radiotherapy techniques have likely reduced the risk, but they may not have eliminated cardiotoxicity, and therefore, the long‐term hazards in the general population still need to be monitored directly. The association between radiotherapy and cardiovascular risk has clinical relevance with respect to individual screening, risk factor modification, and the primary and secondary prevention of heart disease.

Sources of Funding {#jah32266-sec-0027}
==================

This work was supported by National Natural Science Foundation of China (No. 81370285), Guangdong Province Science and Technology Program (No. 2012B031800091), and Guangzhou City Science and Technology Program (No. 201508020057) to Dr Wu; and National Natural Science Foundation of China for Young Scholar (No. 81600260) and Natural Science Foundation of Guangdong Province (No. 2016A030313210) to Dr Cheng.

Disclosures {#jah32266-sec-0028}
===========

None.

Supporting information
======================

###### 

**Table S1.** Studies Included in the Meta‐Analysis That Assessed Cardiac Morbidity and Mortality Associated With Breast Cancer Radiotherapy

**Table S2.** The Quality Assessment of Included Cohort Studies Using the Newcastle‐Ottawa Scale

**Table S3.** The Quality Assessment of Included Case‐Control Studies Using the Newcastle‐Ottawa Scale

**Table S4.** The Quality Assessment of Included Randomized Controlled Studies Using the Modified Jadad Scores

**Figure S1.** Flowchart of the selection of studies included in meta‐analysis.

**Figure S2.** Funnel plots showing association of coronary heart disease and cardiac death with radiotherapy.

**Figure S3.** Forest plot for risk of myocardial infarction and death from coronary heart disease in patients with left‐sided radiotherapy versus right‐sided radiotherapy.

**Figure S4.** Forest plot for risk of coronary heart disease in unirradiated patients with left‐sided versus right‐sided breast cancer.

**Figure S5.** Forest plot for risk of cardiac death in unirradiated patients with left‐sided versus right‐sided breast cancer.

**Figure S6.** Forest plot for risk of death from any cause in patients with left‐sided radiotherapy versus right‐sided radiotherapy.

**Figure S7.** Forest plot for risk of myocardial infarction and death from coronary heart disease in patients with radiotherapy versus those without radiotherapy.

###### 

Click here for additional data file.
